Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

Journal of Clinical Oncology

Volumn 20, Issue 4, 2002, Pages 1075-1086

  Mitchell, Malcolm S ^a   Darrah, Denise ^a   Yeung, David ^a   Halpern, Samuel ^a   Wallace, Anne ^a   Voland, Joseph ^a   Jones, Vicky ^a   Kan Mitchell, June ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; INDIUM 111; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MONOPHENOL MONOOXYGENASE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DROSOPHILA MELANOGASTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEUKAPHERESIS; MELANOMA; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SCINTIGRAPHY; TUMOR BIOPSY;

ANIMALS; ANTIGENS, CD80; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; DROSOPHILA; EPITOPES; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; INFUSIONS, INTRAVENOUS; INTERCELLULAR ADHESION MOLECULE-1; MELANOMA; SKIN NEOPLASMS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME; TYROSINE;

EID: 0037083430     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.4.1075     Document Type: Article

References (21)

1. Principles of tumor immunology and their application to the biomodulation of cancer
2. Principles of biologic therapy
3. Impediments to successful immunotherapy
4. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
5. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
6. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
7. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy
8. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
9. Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma
10. An HLA-A2-restricted: Tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
11. + T cells
12. + T cells: Implications for tumor immunotherapy
13. + T cells usable in immunotherapy
14. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype
15. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma
16. Active specific immunotherapy of melanoma: Phase I trial of allogeneic melanoma lysates and a novel adjuvant
17. The evaluation of limiting dilutions assays
18. Biomodulation: A classification and overview
19. Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results and possible mechanisms of action
20. Principles for adoptive T cell therapy of human viral diseases